HemaCare (OTCMKTS:HEMA) Trading 0.6% Higher – Should You Buy?

HemaCare Co. (OTCMKTS:HEMAGet Free Report)’s stock price rose 0.6% during mid-day trading on Tuesday . The company traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.

HemaCare Price Performance

The stock’s 50-day moving average price is $25.31 and its 200 day moving average price is $25.31.

About HemaCare

(Get Free Report)

HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.

Featured Articles

Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.